Food and Drug Interactions with Monoamine Oxidase Inhibitors: How Safe Are the Newer Agents?

CNS Drugs

Volumn 5, Issue 6, 1996, Pages 403-413

  Berlin, Ivan ^a   Lecrubier, Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIFLAMINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BEFLOXATONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; CAROXAZONE; CIMETIDINE; CLORGYLINE; DEXTROMETHORPHAN; DIGOXIN; EPHEDRINE; FLUVOXAMINE; ISOCARBOXAZID; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PARGYLINE; PETHIDINE; PHENELZINE; PHENPROCOUMON; PHENYLEPHRINE; SELEGILINE; TOLOXATONE; TRANYLCYPROMINE; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG INTERACTION; FOOD; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0029970186     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605060-00001     Document Type: Article

References (63)

1. Hare MLC. Tyramine oxidase. A new enzyme system in liver. Biochem J 1928; 22: 968-79
2. Kline NS. Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol 1958; 2 Suppl. 1: 72-9
3. Zeller EA, Barsky J, Fouts JH, et al. Influence of isonicotinic acid hydrazine and 1-isonicotinyl-2-isopropyl hydrazine in bacterial and mammalian enzymes. Experientia 1952; 8: 349-50
4. Lurie ML, Salzer HM. Tranylcypromine (Parnate) in the ambulatory treatment of depressed patients. Am J Psychiatry 1961; 118: 152-5
5. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963; II: 849-51
6. Simpson GM, de Leon J. Tyramine and new monoamine oxidase inhibitor drugs. Br J Psychiatry 1489; 155 Suppl. 6: 32-7
7. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese [letter]. Lancet 1963; II: 733-4
8. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285-97
9. Knoll J, Glover V, Magyar K, et al. Novel (-)-deprenyl derived selective inhibitors of B-type monoamine oxidase: the relation of structure to their action. Biochem Pharmacol 1978; 27: 1739-47
10. Tiller JWG, Dowling JT, Tung LH, et al. Tyramine-induced cardiac arrhythmias [letter]. N Engl J Med 1985; 313: 266-7
11. Pare CMB, Kline N, Hallstrom C, et al. Will amitriptyline prevent the 'cheese' reaction of monoamine-oxidase inhibitors? Lancet 1982; II: 183-6
12. Pare CMB, Al Mousawi M, Sandler M, et al. Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness. J Affective Dis 1985; 9: 137-41
13. Schulz R, Antonin KH, Hoffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989; 46: 528-36
14. Berlin I, Molinier P. Oral tyramine challenge tests [letter]. Clin Pharmacol Ther 1993; 54: 230-1
15. Korn A, Da Prada M, Raffesberg W, et al. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 1988; 11: 17-23
16. Wijnands S, Chang PC, Blauw GJ, et al. Polentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol 1989; 3: 36-44
17. Bieck PR, Antonin KH. Oral tyramine pressor lest and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988; 8: 237-45
18. Berlin I, Zimmer R, Cournot A, et al. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 1989; 46: 344-51
19. Audebert C, Blin O, Monjanel-Mouterde S, et al. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers. Eur J Clin Pharmacol 1992; 43: 507-12
20. Patat A, Berlin I, Durrieu G, et al. Pressor effect of oral tyramine during treatment with hefloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 1995; 35: 633-43
21. Korn A, Da Prada M, Raffesberg W, et al. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm 1988; Suppl. 26: 57-71
22. Martini A, Bonollo L, Nicolis FB, et al. Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to oral tyramine in man. Br J Clin Pharmacol 1981; 11: 611-5
23. Grind M, Siwers B, Graffner C, et al. Pressor response of oral tyramine in healthy men given amiflamine and placebo. Clin Pharmacol Ther 1986; 40: 155-60
24. Provost JC, Funck-Brentano C, Rovei V, et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther 1992; 52: 384-93
25. Simpson GM, Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 1992; 52: 286-91
26. Bieck PR, Firkusny L, Schick C, et al. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 1989; 45: 260-9
27. Burgess CD, Mellsop GW. Interaction between moclobemide and oral tyramine in depressed patients. Fundam Clin Pharmacol 1989; 3: 47-52
28. Hannah P, Glover V, Sandler M. Tyramine in wine and beer [letter]. Lancet 1988; 1: 879
29. Da Prada M, Zürcher G, Wüthrich I, et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 1988; Suppl. 26: 31-56
30. Shulmun KI, Walker SK, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989; 9: 397-402
31. Tailor SAN, Shulman KI, Walker SE, et al. Hypertensive episode associated with phenelzine and tap beer. A reanalysis of the role of pressor airlines in beer. J Clin Psychopharmacol 1994; 14: 5-14
32. Murray JA, Walker JF, Doyle JS. Tyramine in alcohol-free beer [letter]. Lancet 1988; 1: 1167-8
33. Thakore J, Dinan TG, Kelleher M. Alcohol-free beer and the irreversible monoamine oxidase inhibitors. International Clin Psychopharmacol 1992; 7: 59-60
34. Da Prada M, Zürcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology 1992; 106: S32-S34
35. Baumhackl U, Bizière K, Fischbach R, et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorders (DSM-III): an Austrian double blind multicentre study. Br J Psychiatry 1989; 155 Suppl. 6: 78-83
36. Versiani M, Oggero U, Alterwain P, et al. A double-blind comparative trial of moclobemide versus imipramine and placebo in major depressive episodes. Br J Psychiatry 1989; 155 Suppl. 6: 72-7
37. Guelfi JD, Payan C, Fermanian J, et al. Moclobemide versus clomipramine in endogenous depression. Acta Psychiatr Scand 1992; 160: 519-24
38. Lecrubier Y, Pedariosse AM, Payan C, et al. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. Acta Psychiatr Scand 1995; 92: 260-5
39. Versiani M, Nardi AE, Figueira ILV, et al. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand 1990; Suppl. 360: 21-8
40. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
41. Lejoyeux M, Adès J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 1994; 2: 132-43
42. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991; 11: 55-9
43. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986; 21: 1067-71
44. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone [letter]. Psychosomatics 1992; 2: 235
45. Sandyk R. L-Dopa induced 'serotonin syndrome' in a parkinsonian patient on bromocriptine [letter]. J Clin Psychopharmacol 1986; 6: 194-5
46. Spigset O. Serotonin syndrome caused by a moclobemide-clomipramine interaction [letter]. BMJ 1993; 306: 248
47. Amrein R, Güntert TW, Dingemanse J, et al. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992; 106: S24-S31
48. Korn A, Eichler HG, Fischbach R, et al. Moclobemide, a new reversible MAO inhibitor - interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology 1986; 88: 153-7
49. Luax G, Becker T, Struck M. Switching from MAO-A-inhibitors to tricyclic antidepressants: wash-out still obligatory [abstract]? Psychopharmacology 1988; Suppl. 96: 230
50. Dingemanse J, Kneer J, Fotteler B, et al. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor. J Clin Psychopharmacol 1995; 15: 41-8
51. Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol 1993; 7: 167-80
52. Ebert D, Albert R, May A, et al. Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology 1995; 119: 342-4
53. Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555
54. Lefebvre H, Richard R, Noblet C, et al. Life-threatening pseudophaeochromocytoma after toloxatone, terbutaline, and phenylephrine [letter]. Lancet 1993; 341: 555-6
55. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53: 84-8
56. Stack CG, Rogers P, Linter SPK. Monoamine oxidase inhibitors and anaesthesia. Br J Anaesth 1488; 60: 222-7
57. Monoamine oxidase inhibitors and anesthesia: an update [editorial]. Int Drug Ther Newslett 1989; 24: No. 4
58. Hill S, Yau K, Whitman J. MAOIs to RIMAs in anaesthesia - a literature review. Psychopharmacology 1992; 106: 543-5
59. Schoerlin MP, Mayersohn M, Hoevels B, et al. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor muclobemide. Clin Pharmacol Ther 1991; 49: 32-8
60. Bélanger PM, Atitsé-Gbeassor A. The inhibitory effect of monoamine oxidase inhibitors on hepatic microsomal enzyme systems of rat liver. Pharmacol Res Comm 1981; 13: 819-28
61. Schoerlin MP, Mayersohn M, Korn A, et al. Disposition kinetics of moclobemide, a monoamine oxidase-A inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther 1987; 42: 395-404
62. Gram LF, Brosen K, and the Danish University Antidepressant Group. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br J Clin Pharmacol 1993; 35: 649-52
63. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-7